| Literature DB >> 35662004 |
Timothy M Wilson1, Joshua J Solomon2, M Kristen Demoruelle3.
Abstract
Interstitial lung disease (ILD) is a common manifestation in connective tissue diseases (CTD), such as rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory myositis (IM). ILD is associated with significant morbidity and mortality in nearly all CTD highlighting the critical need for effective treatment strategies in this patient population. In this review, we will summarize the approach to treatment when there is concern for CTD-ILD and highlight recent advancements in therapeutics within various forms of CTD-ILD.Entities:
Mesh:
Year: 2022 PMID: 35662004 PMCID: PMC9308694 DOI: 10.1016/j.coph.2022.102245
Source DB: PubMed Journal: Curr Opin Pharmacol ISSN: 1471-4892 Impact factor: 4.768